A new clinical study shows that Natera's Signatera test identified colorectal cancer recurrence up to 16.5 months earlier than radiologic imaging by detecting traces of tumor DNA in the blood after surgery. The test also identified patients most likely to relapse, both before and after chemotherapy.1 Results were published in the May issue of JAMA Oncology.

Philips and Alverno Laboratories, a provider of high-quality diagnostic testing services, announced that Alverno will fully implement digital pathology in its clinical laboratories. The laboratory network will use Philips IntelliSite Pathology Solution to assess and diagnose all clinical histology cases digitally, instead of using a microscope, with the aim of improving laboratory efficiency, quality and patient safety.

The Clario SmartWorklist intelligently manages picture archiving and communication system (PACS) reading workflow by automatically organizing each radiologist’s daily reading tasks according to their credentials, subspecialty, workload, availability, and more.

Engineers at Rensselaer Polytechnic Institute are working to improve imaging methods in order to make medicine more precise and personalized. This work will be a critical component of a new interdisciplinary research project funded with $1.4 million from the National Institutes of Health (NIH) that seeks to improve radiation therapy for high-risk prostate cancer patients.

Clinical metal artifact reduction sequence (MARS) magnetic resonance imaging (MRI) protocols at 3 Tesla (3T) on hip arthroplasty implants pose minimal risk of thermal injury, according to a recent study. The findings were presented at the American Roentgen Ray Society (ARRS) 2019 Annual Meeting, May 5-10 in Honolulu.

Researchers from Bourgogne University in Dijon, France, showed that use of superparamagnetic iron oxide nanoparticles (NPs) using multimodal positron emission tomography/magnetic resonance imaging (PET/MRI) offers promising improvements in imaging capabilities. The paper is published in the American Chemical Society journal ACS Omega.

ControlRad Inc. announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for its ControlRad Trace and the company has initiated its commercial launch. The ControlRad Trace is the only technology, according to the company, that can be integrated into existing mobile C-arms to reduce radiation in any fluoroscopic imaging procedure.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now